News

Moderna skyrockets 39% after its early trial for a coronavirus vaccine produced antibodies in all 45 patients (MRNA)


Screen Shot 2020 05 18 at 7.59.57 AM

Moderna announced on Monday that its early trial for its coronavirus vaccine produced antibodies in all patients.
Shares of the company surged 39% on Monday.
The company is aiming to have the vaccine ready for emergency use in the fall.
Watch Moderna trade live on Markets Insider.
on Business Insider.

Moderna is soaring after an early trial of its coronavirus vaccine produced positive results, the company announced Monday.

Shares of the pharmaceutical company surged as much as 39% in premarket trading Monday in New York after it announced that all 45 volunteers in a trial for its coronavirus vaccine produced antibodies that may help protect them against the disease.

The phase 1 trial was conducted by the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health.

Read more: GOLDMAN SACHS: Buy these 14 stocks poised to surge in an economic recovery because of their limited exposure to consumers

Moderna plans to have the drug ready for potential emergency use in the fall — a timeline that’s never been seen for vaccine development before. Following the phase 1 trial, the company hopes to soon start a mid-stage study of the vaccine and move to a late-stage trial in July.

Moderna is one of a handful of pharmaceutical companies that have skyrocketed amid the coronavirus crisis as they race to develop drugs to prevent or treat the disease. The pharmaceutical company has gained 241% year-to-date through Friday’s close.

Read more: ‘We have a depression on our hands’: The CIO of a bearish $150 million fund says the market will grind to new lows after the current bounce is over — and warns ‘a lot more pain’ is still to come

Join the conversation about this story »

NOW WATCH: Pathologists debunk 13 coronavirus myths

…read more

Source:: Business Insider

      

(Visited 8 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *